Tata India Pharma & Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV: ₹ 17.5 as on 24-03-2023
Fund Performance
938 people have invested ₹ 22.5L in mutual fund in the last three months
Fund Insights
In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given -2.81% return, outperforming Tata India Pharma & Healthcare Fund Direct Growth by 5.33%
In the last 3 years, DSP Healthcare Fund Direct Growth has given 29.51% return, outperforming Tata India Pharma & Healthcare Fund Direct Growth by 5.25% per annum
In the last 5 years, Nippon India Pharma Fund - Direct Plan - Growth Plan has given 16.07% return, outperforming Tata India Pharma & Healthcare Fund Direct Growth by 0.64% per annum
Over the last 1 year, Tata India Pharma & Healthcare Fund Direct Growth has decreased expense ratio by 7.3% moving from 1.09 to 1.01
Tata India Pharma & Healthcare Fund Direct Growth has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.01% which is lower than the category average expense ratio of 1.67%
INDmoney Rank
Powered by IND quant engine
IND ranking is not available for this fund.
Pros
5Y returns in the top 25% of the category
Beats FD returns for both 3Y & 5Y duration
Cons
3Y returns in the bottom 25% of the category
Tata India Pharma & Healthcare Fund Direct Growth Performance as on (24-Mar-23)
About the Fund
Tata India Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 28 December, 2015. The fund is managed by Meeta Shetty. The fund could potentially beat inflation in the long-run.
Key parameters
1) Tata India Pharma & Healthcare Fund Direct Growth has a NAV of ₹17.4836 as on 24-03-2023.
2) Tata India Pharma & Healthcare Fund Direct Growth has ₹486 Cr worth of assets under management (AUM) as on 31-01-2023 and is less than category average.
3) The fund has an expense ratio 1.01 %.
Tata India Pharma & Healthcare Fund Direct Growth Overview
 | 1.01% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹486 Cr |
 | 28 December, 2015 |
 | ₹5000/₹150 |
 Exit Load | 0.25% |
 | No Lock-in |
 TurnOver | 32.08% |
Fund Distribution as on (28-Feb-23)
Size breakup
Large cap
46.3%
Mid cap
33.2%
Small cap
18.8%
Sector Allocation
Health
100%
Top Holdings of Tata India Pharma & Healthcare Fund Direct Growth as on (28-Feb-23)
Equity Holdings27
Holdings | Weight% | Holdings Trend | 1M Change |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 18.74% | 0% | |
 Cipla Ltd | 11.29% | 0% | |
 Dr Reddy's Laboratories Ltd | 7.21% | 0% | |
 Lupin Ltd | 7.03% | 0% | |
 Alkem Laboratories Ltd | 6.73% | 0% |
See all
Tata India Pharma & Healthcare Fund Direct Growth: Monthly Changes Updates
All changes are between Dec'22 and Feb'23
Fund Performance
- This fund’s returns stands at -3.66% whereas the fund’s underlying benchmark Nifty 500 returns stands at -2.22% as on Feb'23
- This fund underperformed Nifty 500 by 1.44% in Feb'23
AUM Change
- AUM of the fund stands at 485.9 Cr as of Feb'23
- AUM decreased by 17.7 Cr between Feb'23 and Jan'23
Fund Portfolio Changes
Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 18.49% to 19.56%
Lupin Ltd's allocation increased from 7.37% to 7.59%
Ipca Laboratories Ltd's allocation increased from 5.19% to 5.36%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 12.62 % to 12.23 %
Dr Reddy's Laboratories Ltd's allocation decreased from 7.08 % to 6.97 %
Divi's Laboratories Ltd's allocation decreased from 5.42 % to 5.4 %
Large Cap allocation has gone down from 48.3% to 46.3%
Small Cap allocation has gone up from 18.3% to 18.8%
Mid Cap allocation has gone up from 32.2% to 33.2%
Cash allocation has gone up from 1.2% to 1.7%
Top Sector in February was Health
Feb'23
Health
100%
Jan'23
Health
100%
Gainers & Losers in Tata India Pharma & Healthcare Fund Direct Growth portfolio as on (28-Feb-23)
Top Growth Drivers | 1M Return |
|---|---|
 Procter & Gamble Health Ltd | 14.1% |
 Aurobindo Pharma Ltd | 12.1% |
 Alkem Laboratories Ltd | 4.8% |
Peer Analysis
Tata India Pharma & Healthcare Fund Direct Growth Fund Manager
Meeta Shetty
Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth, since 9 March 2021
Top funds managed
Fund Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 8.03% since inception which is less than its category average return of 13.52%
Fund Allocations
This fund has an allocation of 98.3% in Equity, 0% in Debt and 1.7% in Cash related instruments
AUM size ₹486 Cr
This fund has AUM of ₹486 Cr which is less than its category average of ₹ 1251 Cr
Expense Ratio 1.01%
This fund has an expense ratio of 1.01% which is less than its category average expense ratio of 1.56%
Frequently Asked Questions
The current NAV of Tata India Pharma & Healthcare Fund Direct Growth is 17.41 as on 20-Mar-2023.
Existing (Absolute + CAGR)
Tata India Pharma & Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -3.85% | -3.85% |
6 Month Returns | -2.63% | -2.63% |
1 Year Returns | -7.52% | -7.52% |
3 Years Returns | 83.43% | 22.41% |
5 Years Returns | 99.24% | 14.78% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.01 as on February 2023
486 Cr as on February 2023
Sun Pharmaceuticals Industries Ltd(18.74%),Cipla Ltd(11.29%),Dr Reddy's Laboratories Ltd(7.21%),Lupin Ltd(7.03%),Alkem Laboratories Ltd(6.73%) as on February 2023
The alpha ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 5.24 | 4.57 | 7.31 |
As on February 2023
The alpha for Tata India Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 0.97 | 0.8 | 0.74 |
As on February 2023
The Beta for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | -0.6 | 0.79 | 0.55 |
As on February 2023
The sharpe ratio for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 12.65 | 19.41 | 17.9 |
As on February 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.71 as on February 2023. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.39 as on February 2023. It tells the consistency of the fund in generating superior risk-adjusted performance
Meeta Shetty is the fund manager of Tata India Pharma & Healthcare Fund Direct Growth
The Exit load of Tata India Pharma & Healthcare Fund Direct Growth is 0.25%